Skip to content

The prevention of postoperative nausea and vomiting following general anesthesia and the monitoring of intraoperative QTc safety

Randomized Controlled Trial of Ondansetron in Combination with Ondansetron for the Effects on PONV and QTc

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109721
Enrollment
Unknown
Registered
2025-09-24
Start date
2025-10-01
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative nausea and vomiting following general anesthesia

Interventions

Experimental group: Oliceridine + Ondansetron (O group) :Prior to this trial, ED50 and ED95 studies of olanzapine for hysteroscopic surgery were conducted. Subsequently, groups were randomized using a
Control group: Sufentanil + Ondansetron (S group):The control group (Group S) received intravenous administration of 0.1 µg/kg sufentanil and 4 mg ondansetron after entering the operating room and com

Sponsors

Wang Chenggang(Study sponsor)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Age 18–65 years; 2.ASA classification I–II; Body mass index (BMI) 18–30 kg/m^2; 3.Mallampati classification I–II; Electrocardiogram QTc interval <460 ms; 4.No contraindications to medication (uncontrolled blood pressure high/low blood pressure, bradycardia, thyroid function decreased, concomitant use of potent CYP3A4 inhibitors or benzodiazepines)

Exclusion criteria

Exclusion criteria: 1.Electrolyte imbalance (blood potassium 5.5 mmol/L); 2.History of cardiovascular disorder (coronary heart disease, heart failure, cardiac arrhythmia); 3.Hepatic or renal insufficiency (ALT/AST >2 times the upper limit, eGFR = grade 3, Child-Pugh class B/C); Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Incidence of nausea and vomiting within 24 hours postoperatively;QTc interval variation;

Secondary

MeasureTime frame
Incidence of PONV within 0-6 hours postoperatively;Time of initial request for antiemetic medication;The proportion of patients experiencing clinically significant QTc prolongation (greater than 30 ms from baseline);Incidence of intraoperative adverse events (including blood pressure fluctuations exceeding 20% from baseline, oxygen saturation below 95%, intraoperative awareness, and intraoperative movement);Incidence of other opioid-related adverse reactions (including constipation, dry mouth, drowsiness, pruritus, urinary retention) following surgery;Oliceridine characteristic EEG spectrum;EEG spectrum analysis of oxazepam combined with propofol;Intraoperative vital signs (including blood pressure, oxygen saturation, Ai index, respiratory rate, etc.);Quality of Recovery-40 Scale (QoR-40);Intraoperative parameters (fluid volume, oliceridine dosage, sufentanil dosage, propofol dosage, operative time);NRS pain score preoperatively and upon discharge from PACU;

Countries

China

Contacts

Public ContactWang Chenggang

Shanxi Provincial Hospital of Traditional Chinese Medicine / Shanxi Provincial Institute of Traditional Chinese Medicine

wgangw@163.com+86 138 3415 7501

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026